Mallinckrodt PLC (NYSE:MNK) was up 5.1% on Wednesday . The company traded as high as $65.66 and last traded at $65.31, with a volume of 764,542 shares trading hands. The stock had previously closed at $62.16.

A number of equities research analysts have weighed in on MNK shares. Wells Fargo & Co. reiterated a “buy” rating on shares of Mallinckrodt PLC in a research report on Tuesday, May 3rd. Mizuho reiterated a “buy” rating and set a $80.00 price target (up from $78.00) on shares of Mallinckrodt PLC in a research report on Thursday, April 28th. Morgan Stanley reiterated a “buy” rating on shares of Mallinckrodt PLC in a research report on Wednesday, April 27th. Zacks Investment Research upgraded shares of Mallinckrodt PLC from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research report on Thursday, May 5th. Finally, Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Mallinckrodt PLC in a research note on Wednesday, May 4th. Three analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Mallinckrodt PLC has a consensus rating of “Buy” and a consensus price target of $91.42.

The firm has a market cap of $7.38 billion and a price-to-earnings ratio of 16.95. The company’s 50-day moving average price is $61.08 and its 200 day moving average price is $62.51.

Mallinckrodt PLC (NYSE:MNK) last posted its earnings results on Tuesday, May 3rd. The company reported $2.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.29. The business had revenue of $918 million for the quarter, compared to analyst estimates of $878.70 million. During the same period last year, the company posted $1.72 EPS. The firm’s revenue for the quarter was up 12.1% compared to the same quarter last year. Equities analysts predict that Mallinckrodt PLC will post $8.28 earnings per share for the current fiscal year.

In other news, VP Hugh M. O’neill acquired 1,653 shares of the stock in a transaction on Tuesday, May 10th. The stock was bought at an average price of $60.99 per share, with a total value of $100,816.47. Following the completion of the transaction, the vice president now directly owns 15,623 shares of the company’s stock, valued at $952,846.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Matthew K. Harbaugh acquired 500 shares of the stock in a transaction on Tuesday, May 10th. The stock was purchased at an average cost of $59.37 per share, with a total value of $29,685.00. Following the transaction, the chief financial officer now directly owns 56,036 shares of the company’s stock, valued at $3,326,857.32. The disclosure for this purchase can be found here.

A number of hedge funds have recently modified their holdings of the stock. Gamco Investors INC. ET AL purchased a new stake in shares of Mallinckrodt PLC during the fourth quarter valued at about $1,161,000. Suntrust Banks Inc. increased its stake in shares of Mallinckrodt PLC by 9.4% in the fourth quarter. Suntrust Banks Inc. now owns 29,987 shares of the company’s stock valued at $2,236,000 after buying an additional 2,574 shares during the period. Nationwide Fund Advisors increased its stake in shares of Mallinckrodt PLC by 1.8% in the fourth quarter. Nationwide Fund Advisors now owns 34,985 shares of the company’s stock valued at $2,611,000 after buying an additional 606 shares during the period. Aberdeen Asset Management PLC UK increased its stake in shares of Mallinckrodt PLC by 4.6% in the fourth quarter. Aberdeen Asset Management PLC UK now owns 63,300 shares of the company’s stock valued at $3,710,000 after buying an additional 2,798 shares during the period. Finally, Affinity Investment Advisors LLC increased its stake in shares of Mallinckrodt PLC by 40.8% in the fourth quarter. Affinity Investment Advisors LLC now owns 51,990 shares of the company’s stock valued at $3,880,000 after buying an additional 15,060 shares during the period.

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.